今日聚焦 1、恒瑞医药：获得HRS-5041片临床试验批准通知书 恒瑞医药公告称，公司及子公司成都盛迪医药收到国家药监局核准签发的HRS-5041片《药物临床试验 批准通知书》，同意该药联合用药用于前列腺癌的临床试验。HRS-5041是公司开发的新型、高效、选 择性的AR-PROTAC(雄激素受体-蛋白降解靶向嵌合体)小分子，拟用于治疗前列腺癌。HRS-5041对野生 型及各类突变体的AR蛋白有显著的降解作用，与二代AR抑制剂相比，有克服耐药的潜力。经查询，目 前国内外暂时无同类产品获批上市。 2、万华化学：股东Prime Partner International Limited拟减持不超过0.54%公司股份 万华化学公告称，持股5%以上股东Prime Partner International Limited计划自减持计划公告之日起15个交 易日之后的3个月内，通过集中竞价及/或大宗交易方式减持不超过公司总股本0.54%的股份，即不超过 1700万股。减持原因为自身资金需求及财务计划。减持期间为2025年8月22日至2025年11月21日。减持 股份来源为非公开发行。 3、山鹰国际：拟29.77亿元设立合 ...

Core Viewpoint - The company anticipates a significant decline in net profit for the first half of 2025, primarily due to adverse market conditions and increased competition in the oil and petrochemical sectors [1] Group 1: Financial Performance - The company expects a net profit attributable to shareholders of 20.1 billion to 21.6 billion yuan for the first half of 2025, representing a year-on-year decrease of 39.5% to 43.7% [1] - The decline in profit is attributed to a sharp drop in international crude oil prices, intense competition in the oil and petrochemical markets, and low margins in the chemical market [1] Group 2: Operational Strategy - In response to the challenging operating environment, the company is intensifying efforts to optimize production and operations while strictly controlling costs and expenses [1]

Core Insights - The 2025 Fortune Global 500 list reveals that the total revenue of the listed companies for 2024 is approximately $41.7 trillion, representing a year-on-year growth of about 1.8%, exceeding one-third of the global GDP [1] - The total net profit of these companies has increased by approximately 0.4% year-on-year, amounting to around $2.98 trillion [1] - Walmart continues to lead as the largest company globally with revenues of approximately $681 billion, marking its twelfth consecutive year at the top [1] Company Rankings - JD.com ranks 44th, up 3 places from last year, maintaining its position as the highest-ranked private company from mainland China [2] - Alibaba's ranking improved by 7 places to 63rd, while Tencent rose 25 places to 116th [2] - Pinduoduo saw the most significant increase, climbing 176 places to 266th, and Meituan moved up 57 places to 327th [2] Profitability Insights - Saudi Aramco remains the most profitable company globally with a profit of approximately $105 billion, despite a year-on-year decline of about 13% [2] - Alphabet, the parent company of Google, ranks second in profitability with a net profit of $100.1 billion, surpassing Apple, which ranks third with $93.7 billion [2] - Berkshire Hathaway and Microsoft follow, with profits of over $88.9 billion and $88.1 billion, respectively [2] - Nvidia's profit surged by approximately 145% to around $72.9 billion, marking its first entry into the top ten profitability rankings [2] - The Industrial and Commercial Bank of China ranks as the highest Chinese company in net profit, exceeding $50.8 billion and placing 10th globally [2]

Group 1: Public Fund Industry - The total net asset value of public funds in China reached a historical high of 34.39 trillion yuan as of June 30, 2025, with a month-on-month increase of 651.9 billion yuan, representing a growth rate of 1.93% [1] Group 2: Technology and Security - The National Internet Information Office of China held discussions with NVIDIA regarding security risks associated with the H20 computing chip, following concerns about vulnerabilities and backdoor issues [2] - IDC predicts that the global robotics market will exceed $400 billion by 2029, with China accounting for nearly half of this market and leading with a compound annual growth rate of nearly 15% [2] Group 3: Gaming Industry - The domestic gaming market in China achieved a sales revenue of 168 billion yuan in the first half of 2025, marking a year-on-year growth of 14.08% and setting a new record [2] Group 4: Corporate Developments - Moutai's official authorized stores have begun to enter the Meituan flash purchase platform, indicating a strategic move to enhance distribution channels [3] - Huashan Fund experienced a significant personnel change, with Xu Yong appointed as the Party Secretary, potentially leading to a future role as Chairman [3] - Zhejiang Rural Commercial Bank's total asset scale surpassed 7 trillion yuan as of June 30, 2025, with a non-performing loan ratio of 0.94% [3] Group 5: Market Reactions - Three major steel companies announced a suspension of molybdenum iron procurement to combat irrational market speculation [3] Group 6: IPO and Financing - The China Securities Regulatory Commission approved the IPO registration of Yunhan Chip City on the Growth Enterprise Market [4] - Lege Co., Ltd. plans to register and issue medium-term notes not exceeding 800 million yuan to repay debts and supplement working capital [5][6] - Tianhe Magnetic Materials obtained a project filing notice for a 12,000-ton deep processing project with a total investment of 250 million yuan [7] Group 7: Financial Performance - Daodaquan reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [9] - Jiejia Weichuang expects a net profit increase of 38.65% to 59.85% for the first half of 2025, projecting a profit between 1.7 billion and 1.96 billion yuan [10] - Sinopec anticipates a net profit decline of 39.5% to 43.7% for the first half of 2025, estimating profits between 20.1 billion and 21.6 billion yuan [11] Group 8: Market Overview - The A-share market experienced fluctuations, with the ChiNext index rising over 8% in July, while the Shanghai Composite Index lost the 3600-point mark [12]

Group 1 - Jiejia Weichuang expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, representing a year-on-year increase of 38.65% to 59.85% [1] - Micron Biotech's CS231295 clinical trial application has been approved by the FDA for treating advanced solid tumors [1] - Sinopec anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year [2] Group 2 - High Energy Environment has obtained a loan commitment letter from a financial institution for share repurchase [2] - Electric Power Investment Energy received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inadequate disclosure in its semi-annual report [3] - Zhejiang University Net New won a bid for an intelligent engineering project worth 94.2712 million yuan [5] Group 3 - Daodaoquan reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [8] - New Light Optoelectronics expects a net loss of 19 million to 23 million yuan for the first half of 2025 [9] - Aihua Pharmaceutical's two probiotic powder registration applications have been accepted [10] Group 4 - Xinhui Electric's subsidiary signed a product sales framework contract for commercial and household robots [11] - Baida Precision Engineering's subsidiary obtained 134,500 square meters of industrial land use rights [12] - Haiyang Technology's chief engineer resigned for personal reasons [13] Group 5 - Tianhe Magnetic Materials received a project filing notice for a 12,000-ton magnetic material deep processing project [22] - Wanlima is the pre-selected unit for a procurement project worth 43.835 million yuan from China Southern Airlines [24] - Yipin Hong's subsidiaries obtained two drug registration certificates [25] Group 6 - Zhejiang Jiaoke's subsidiary signed new construction projects worth 4.783 billion yuan in the second quarter [27] - Shenglan Co. received approval for issuing convertible bonds [29] - Jimi Technology expects a net profit of 88.6622 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [31] Group 7 - Dingtong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06% [32] - Huaheng Biological is planning to list on the Hong Kong Stock Exchange [34] - Yuntian Lihui submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [36] Group 8 - Nanchip Technology expects a net profit of 108.8 million to 133.1 million yuan for the first half of 2025, a decrease of 35.09% to 47.03% year-on-year [43] - Anglikang's Mesobam injection has received a drug registration certificate [44] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.998% [45]

对于净利润下滑原因，中国石化表示，2025年上半年，面对严峻复杂的经营形势，公司加大生产经营优 化力度，从严从紧控制成本费用。但受国际原油价格大幅下跌、石油石化市场竞争激烈、化工市场毛利 低迷等因素影响，上半年归属于母公司股东的净利润同比下降。（每经，德塔） 【#中国石化预计上半年净利润超200亿#】7月31日，中国石化公告，按中国企业会计准则，预计公司 2025年上半年实现归属于母公司股东的净利润为人民币201亿元至人民币216亿元，与上年同期相比，将 下降39.5%至43.7%。 ...

Core Viewpoint - China Petroleum & Chemical Corporation (Sinopec) expects a significant decline in net profit for the first half of 2025, projecting a range of RMB 20.1 billion to RMB 21.6 billion, which represents a decrease of 39.5% to 43.7% compared to the same period last year [1] Group 1: Financial Performance - The projected net profit for the first half of 2025 is between RMB 20.1 billion and RMB 21.6 billion [1] - This represents a year-on-year decline of 39.5% to 43.7% [1] Group 2: Operational Challenges - The company is facing severe and complex operational conditions [1] - Sinopec has intensified efforts to optimize production and control costs strictly [1] Group 3: Market Influences - The decline in net profit is attributed to several factors, including a significant drop in international oil prices, intense competition in the oil and petrochemical markets, and low margins in the chemical market [1]

Core Viewpoint - China Petroleum & Chemical Corporation (Sinopec) expects a significant decline in net profit for the first half of 2025, projecting a range of RMB 20.1 billion to RMB 21.6 billion, representing a 39% decrease compared to the same period last year [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of RMB 20.1 billion to RMB 21.6 billion for the first half of 2025 [1] - This projected profit reflects a 39% decline compared to the same period in the previous year [1] Group 2: Operational Challenges - The company is facing a challenging operating environment, characterized by a significant drop in international crude oil prices, intense competition in the oil and petrochemical markets, and low margins in the chemical market [1] - In response to these challenges, the company is intensifying efforts to optimize production and operations while strictly controlling costs and expenses [1]

股票代码：600028 股票简称：中国石化 公告编号：2025-29 中国石油化工股份有限公司 2025 年半年度业绩提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 按中国企业会计准则，预计公司 2025 年上半年实现归属于母公司股东的 净利润为人民币 201 亿元至人民币 216 亿元，与上年同期相比，将下降 39.5%至 43.7%。 按中国企业会计准则，预计公司 2025 年上半年实现归属于母公司股东的 扣除非经常性损益后的净利润为人民币 200 亿元至人民币 215 亿元，与上年同期 相比，将下降 39.6%至 43.8%。 一、本期业绩预告情况 （一） 业绩预告期间 1 性损益后的净利润为人民币 200 亿元至人民币 215 亿元，与上年同期相比，将下 降 39.6%至 43.8%。 （三） 本次预计的业绩未经审计。 二、上年同期业绩情况 （一）归属于母公司股东的净利润：人民币 357.03 亿元。 （二）归属于母公司股东的扣除非经常性损益后的净利润：人民币 355.82 亿元。 （三）基 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任何損失承擔任何責任。 （在中華人民共和國註冊成立的股份有限公司） （證券代號：00386） 2025年半年度業績提示性公告 重要內容提示： 一、本期業績預告情況 （一）業績預告期間 （二）歸屬於母公司股東的扣除非經常性損益後的淨利潤：人民币 355.82 億元。 1 按中國企業會計準則，預計公司 2025 年上半年實現歸屬於母公司股東的淨利 潤為人民幣 201 億元至人民幣 216 億元，與上年同期相比，將下降 39.5%至 43.7%。 按中國企業會計準則，預計公司 2025 年上半年實現歸屬於母公司股東的扣除 非經常性損益後的淨利潤為人民幣 200 億元至人民幣 215 億元，與上年同期相 比，將下降 39.6%至 43.8%。 （三）基本每股收益：人民幣 0.296 元。 （四）扣除非經常性損益後的基本每股收益：人民幣 0.295 元。 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）業績預告情況 ...